M. Maynadié, D. Angelis, R. Marcos-gragera, R. Visser, O. Allemani et al., Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study, Haematologica, vol.98, issue.2, pp.230-238, 2013.
DOI : 10.3324/haematol.2012.064014

A. Monnereau, L. Remontet, M. Maynadié, F. Binder-foucard, A. Belot et al., Estimation nationale de l'incidence des cancers en France entre, 1980.

S. Dinner, F. Giles, and J. Altman, New strategies for relapsed acute myeloid leukemia, Current Opinion in Hematology, vol.21, issue.2, pp.79-86, 2014.
DOI : 10.1097/MOH.0000000000000018

A. Bosi, D. Laszlo, M. Labopin, J. Reffeirs, M. Michallet et al., Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation, Journal of Clinical Oncology, vol.19, issue.16, pp.3675-84, 2001.
DOI : 10.1200/JCO.2001.19.16.3675

H. Döhner, E. Estey, D. Grimwade, S. Amadori, F. Appelbaum et al., Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, vol.129, issue.4, pp.424-471, 2017.
DOI : 10.1182/blood-2016-08-733196

A. Gratwohl, M. Pasquini, M. Aljurf, Y. Atsuta, H. Baldomero et al., One million haemopoietic stem-cell transplants: a retrospective observational study, The Lancet Haematology, vol.2, issue.3, pp.91-100
DOI : 10.1016/S2352-3026(15)00028-9

G. Juliusson, K. Karlsson, V. Lazarevic, A. Wahlin, M. Brune et al., Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia, Cancer, vol.46, issue.Suppl. 1, pp.4238-4284, 1997.
DOI : 10.1038/bmt.2010.69

G. Orti, J. Sanz, A. Bermudez, D. Caballero, C. Martinez et al., Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Espa??ol de Trasplante Hematopoyetico, Biology of Blood and Marrow Transplantation, vol.22, issue.3, pp.584-592, 2016.
DOI : 10.1016/j.bbmt.2015.11.012

R. Vrhovac, M. Labopin, F. Ciceri, J. Finke, E. Holler et al., Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes, Bone Marrow Transplantation, vol.9, issue.2, 2016.
DOI : 10.1038/sj.bmt.1705011

D. Pollyea, A. Artz, W. Stock, C. Daugherty, L. Godley et al., Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation, Bone Marrow Transplantation, vol.12, issue.11, pp.1027-1059, 2007.
DOI : 10.1016/S0301-472X(03)00225-X

D. Porter, E. Alyea, J. Antin, M. Delima, E. Estey et al., NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.16, issue.11, pp.1467-503, 2010.
DOI : 10.1016/j.bbmt.2010.08.001

M. Christopeit, When is second allogeneic HSCT for relapse of acute leukaemia an option? Bone Marrow Transplantation, Feb, vol.51, issue.2, pp.184-189, 2016.

M. Thakar and S. Forman, ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?, Hematology, vol.2009, issue.1, pp.414-422, 2009.
DOI : 10.1182/asheducation-2009.1.414

G. Andreola, M. Labopin, D. Beelen, P. Chevallier, R. Tabrizi et al., Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ???10 years, Bone Marrow Transplantation, vol.86, issue.12, pp.1508-1520, 2015.
DOI : 10.1016/j.bbmt.2011.11.017

J. Mehta, R. Powles, J. Treleaven, C. Horton, S. Meller et al., Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy, Bone Marrow Transplantation, vol.19, issue.7, pp.709-728, 1997.
DOI : 10.1038/sj.bmt.1700720

M. Eapen, S. Giralt, M. Horowitz, J. Klein, J. Wagner et al., Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant, Bone Marrow Transplantation, vol.34, issue.8, 2004.
DOI : 10.1038/sj.bmt.1704645

T. Ruutu, L. De-wreede, A. Van-biezen, R. Brand, M. Mohty et al., Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT, Bone Marrow Transplantation, vol.19, issue.12, pp.1542-50, 2015.
DOI : 10.1038/sj.bmt.1704761

B. Savani, S. Mielke, N. Reddy, S. Goodman, M. Jagasia et al., Management of relapse after allo-SCT for AML and the role of second transplantation, Bone Marrow Transplantation, vol.26, issue.12, pp.769-77, 2009.
DOI : 10.4049/jimmunol.169.8.4253

B. Shaw, G. Mufti, S. Mackinnon, J. Cavenagh, R. Pearce et al., Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant, Bone Marrow Transplantation, vol.74, issue.12, pp.783-792, 2008.
DOI : 10.1111/j.1423-0410.1998.tb05438.x

H. Göksoy and M. Arat, The use of second allogeneic hematopoietic stem cell transplantation for hematologic malignancies relapsed after the first: Does it worth to do?, Transfusion and Apheresis Science, vol.54, issue.1, pp.91-99, 2016.
DOI : 10.1016/j.transci.2016.01.020

A. Gratwohl, M. Stern, R. Brand, J. Apperley, H. Baldomero et al., Risk score for outcome after allogeneic hematopoietic stem cell transplantation, Cancer, vol.25, issue.20, pp.4715-4741, 1920.
DOI : 10.1002/cncr.24531

M. Sorror, M. Maris, R. Storb, F. Baron, B. Sandmaier et al., Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, Blood, vol.106, issue.8, pp.2912-2921, 2005.
DOI : 10.1182/blood-2005-05-2004

K. Rezvani, E. Kanfer, D. Marin, I. Gabriel, A. Rahemtulla et al., EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure, Biology of Blood and Marrow Transplantation, vol.18, issue.2, pp.235-275, 2012.
DOI : 10.1016/j.bbmt.2011.06.010

J. Radich, J. Sanders, C. Buckner, P. Martin, F. Petersen et al., Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens., Journal of Clinical Oncology, vol.11, issue.2, pp.304-317, 1993.
DOI : 10.1200/JCO.1993.11.2.304

A. Gratwohl, J. Hermans, J. Goldman, W. Arcese, E. Carreras et al., Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation, The Lancet, vol.352, issue.9134, pp.1087-92, 1998.
DOI : 10.1016/S0140-6736(98)03030-X

C. Hosing, R. Saliba, M. Shahjahan, E. Estey, D. Couriel et al., Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia, Bone Marrow Transplantation, vol.18, issue.2, pp.157-62, 2005.
DOI : 10.1038/sj.bmt.1701146

J. Bay, A. Cabrespine, C. Faucher, R. Tabrizi, P. Bordigoni et al., Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from the SFGM-TC, Biology of Blood and Marrow Transplantation, vol.18, issue.2, pp.250-256, 2012.
DOI : 10.1016/j.bbmt.2011.06.015

J. Passweg, H. Baldomero, P. Bader, C. Bonini, S. Cesaro et al., Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplantation, Feb, vol.52, issue.2, pp.191-197, 2017.

T. Schroeder, A. Czibere, U. Platzbecker, G. Bug, L. Uharek et al., Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation, Leukemia, vol.26, issue.6, pp.1229-1264, 2013.
DOI : 10.1200/JCO.2008.16.0259

S. Santourlidis, H. Trompeter, S. Weinhold, B. Eisermann, K. Meyer et al., Crucial Role of DNA Methylation in Determination of Clonally Distributed Killer Cell Ig-like Receptor Expression Patterns in NK Cells, The Journal of Immunology, vol.169, issue.8, pp.4253-61, 2002.
DOI : 10.4049/jimmunol.169.8.4253

R. Stone, S. Mandrekar, and C. Laumann, Midostaurin, a multi-targeted kinase inhibitor, improves overall survival when added to standard chemotherapy in adults age 18 ? 60 with FLT3 mutant acute myeloid leukemia (AML): results from a randomized, prospective, placebo-controlled, double-blind trial, CALGB 10603, 2015.

M. Davids, H. Kim, P. Bachireddy, C. Costello, R. Liguori et al., Ipilimumab for Patients with Relapse after Allogeneic Transplantation, New England Journal of Medicine, vol.375, issue.2, pp.143-53, 2016.
DOI : 10.1056/NEJMoa1601202

J. Albring, S. Inselmann, T. Sauer, C. Schliemann, B. Altvater et al., PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation, Bone Marrow Transplantation, vol.52, issue.2, 2017.
DOI : 10.1016/j.ejca.2015.11.016

P. Christopoulos, C. Schmoor, M. Waterhouse, R. Marks, R. Wäsch et al., Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML, Bone Marrow Transplantation, vol.25, issue.7, pp.901-908
DOI : 10.1016/j.bbmt.2011.07.012

Z. Mciver, F. Yin, T. Hughes, M. Battiwalla, S. Ito et al., Second hematopoietic SCT for leukemia relapsing after myeloablative T cell-depleted transplants does not prolong survival, Bone Marrow Transplantation, vol.48, issue.9, pp.1192-1199, 2013.
DOI : 10.1182/blood-2009-10-248997

M. Mrsíc, M. Horowitz, K. Atkinson, J. Biggs, R. Champlin et al., Second HLA-identical sibling transplants for leukemia recurrence, Bone Marrow Transplant, vol.9, issue.4, pp.269-75, 1992.

M. Michallet, M. Tanguy, G. Socié, A. Thiébaut, A. Belhabri et al., Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM), British Journal of Haematology, vol.300, issue.2
DOI : 10.1038/bjc.1977.1

A. Muñoz, I. Badell, T. Olivé, A. Verdeguer, P. Gómez et al., Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON) Haematologica, 2002.

A. Barrett, F. Locatelli, J. Treleaven, A. Gratwohl, R. Szyd?o et al., Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A REPORT BY THE EBMT LEUKAEMIA WORKING PARTY, British Journal of Haematology, vol.7, issue.4, pp.567-74, 1991.
DOI : 10.1038/bjc.1977.1

F. Ravandi, H. Kantarjian, A. Cohen, M. Davis, O. Brien et al., Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study, Bone Marrow Transplantation, vol.27, issue.12, pp.1221-1226, 2001.
DOI : 10.1038/sj.bmt.1703028

J. Russell, T. Bowen, C. Brown, J. Luider, J. Ruether et al., Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells, Bone Marrow Transplant, 1996.

M. Christopeit, O. Kuss, J. Finke, U. Bacher, D. Beelen et al., Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change, Journal of Clinical Oncology, vol.31, issue.26, pp.313259-71, 2013.
DOI : 10.1200/JCO.2012.44.7961

N. Bejanyan, D. Weisdorf, B. Logan, H. Wang, S. Devine et al., Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study, Biology of Blood and Marrow Transplantation, vol.21, issue.3, pp.454-463, 2015.
DOI : 10.1016/j.bbmt.2014.11.007

K. Kishi, S. Takahashi, H. Gondo, S. Shiobara, A. Kanamaru et al., Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes, Bone Marrow Transplantation, vol.19, issue.5, pp.461-467, 1997.
DOI : 10.1038/sj.bmt.1700680

J. Levine, T. Braun, S. Penza, P. Beatty, K. Cornetta et al., Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation, Journal of Clinical Oncology, vol.20, issue.2, pp.405-417, 2002.
DOI : 10.1200/JCO.2002.20.2.405

A. Raiola, A. Dominietto, C. Di-grazia, T. Lamparelli, F. Gualandi et al., Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts, Biology of Blood and Marrow Transplantation, vol.20, issue.10, pp.1573-1582, 2014.
DOI : 10.1016/j.bbmt.2014.05.029

M. Rubio, Conditionnements avant allogreffe, Hematologie, vol.19, pp.11-14, 2013.

S. Yeh, C. Lin, C. Lin, W. Lo, T. Chen et al., Second haploidentical peripheral blood stem cell transplantation for treatment of acute leukemia with relapse after first allogeneic peripheral blood stem cell transplantation, Bone Marrow Transplantation, vol.18, issue.7, pp.1001-1004
DOI : 10.1016/j.bbmt.2012.06.019

L. Arfons, M. Tomblyn, V. Rocha, and H. Lazarus, Second hematopoietic stem cell transplantation in myeloid malignancies, Current Opinion in Hematology, vol.16, issue.2, pp.112-135, 2009.
DOI : 10.1097/MOH.0b013e3283257a87

M. Christopeit, Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change, Journal of Clinical Oncology, vol.31, issue.26, pp.313259-71, 2013.
DOI : 10.1200/JCO.2012.44.7961

R. Vrhovac, Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes, Bone Marrow Transplantation, vol.9, issue.2, pp.186-93, 2016.
DOI : 10.1038/sj.bmt.1705011